Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851395 · ClinicalTrials.gov registry record
Rapid Autopsy and Procurement of Cancer Tissue
A clinical trial of Mesothelioma and Lung Cancers, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 275
- Enrollment target
- 1
- Study location
NCT01851395 is a study of Mesothelioma and Lung Cancers that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 275 participants, above the 192-participant average among 46 other Mesothelioma trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01851395, a study of Mesothelioma and Lung Cancers, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 275 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Individuals with cancer of the lung, chest cavity, ovary, or bladder, as well as patients who have been treated with adoptive cell therapy unfortunately commonly succumb to their disease. Some agree to donate their bodies to cancer research that may help the medical community better understand these diseases. Studies of cancer tumor tissue obtained soon after death may be used to answer questions about the origins, progression, and treatment of cancer. Researchers want to conduct a study that involves planned collection of cancer tumor tissue shortly after death. To do so, they will arrange to provide inpatient hospice care for people with lung cancer, ovarian cancer, bladder cancer, or patients who have been treated with adoptive cell therapy. \<TAB\> Objectives: \- To collect cancer tissue biopsy samples as soon as possible after death. Eligibility: \- Individuals who have cancer of the lung, chest cavity, ovary, or bladder, or those who have been treated with adoptive cell therapy and are planning to receive end-of-life hospice care are eligible to participate. Design: * Participants will agree to receive inpatient hospice care at the National Institutes of Health Clinical Center. Full details on end-of-life care preference will be acknowledged. * An autopsy will be performed at the clinical center within 3 hours of death. Tumor tissue will be collected from the primary site of cancer and from any areas of the body to which the cancer has spread. * Participants will not receive further cancer treatments as part of this study. This is a tissue collection study only.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2013-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01851395
The ClinicalTrials.gov registry entry for NCT01851395 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 46 other Mesothelioma trials with a reported enrollment target (43% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Mesothelioma appearing as the primary indexed condition, and to 0 interventions.
NCT01851395 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01851395 about?
NCT01851395 is a clinical study titled "Rapid Autopsy and Procurement of Cancer Tissue". Background: \- Individuals with cancer of the lung, chest cavity, ovary, or bladder, as well as patients who have been treated with adoptive cell therapy unfortunately commonly succumb to their disease. Some agree to donate their bodies to cancer research that may help the medical community better ...
What is the current status of trial NCT01851395?
This trial is currently recruiting. The enrollment target is 275 participants. The study started on 2013-12-30.
What conditions does trial NCT01851395 study?
This clinical trial studies the following conditions: Mesothelioma, Lung Cancers, Thymus Tumors, Adoptive Cellular Therapy, Genitourinary Cancers.
Who is sponsoring clinical trial NCT01851395?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01851395 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RECRUITING
-
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
RECRUITING · Phase 1
-
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.